Pub Date : 2016-10-01Epub Date: 2016-09-05DOI: 10.4172/2329-6771.1000178
Brian I Carr, Vito Guerra, Edoardo G Giannini, Fabio Farinati, Francesca Ciccarese, Gian Ludovico Rapaccini, Maria Di Marco, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Alberto Masotto, Franco Trevisani
A Hepatocellular (HCC) Aggressiveness Index was recently constructed, consisting of the sum of the scores for the 4 clinical parameters of maximum tumor size, multifocality, presence of portal vein thrombus and blood alphafetoprotein levels. It was observed that there was an association with several liver function tests. We have now formed a Liver Index from the 4 liver parameters with the highest hazard ratios with respect to HCC aggressiveness, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin and platelet levels (cirrhosis surrogate). We found that the scores for the Liver Index related significantly to survival, but also to the Aggressiveness Index and to its individual HCC components as well as showing significant trends with the components. These results support the hypothesis that liver function is not only an important prognostic factor in HCC patients, but may also be involved in HCC biology and aggressiveness. Blood albumin, GGTP, albumin and platelet levels were used to create a Liver Index that related significantly to parameters of HCC aggressiveness.
{"title":"A Liver Index and its Relationship to Indices of HCC Aggressiveness.","authors":"Brian I Carr, Vito Guerra, Edoardo G Giannini, Fabio Farinati, Francesca Ciccarese, Gian Ludovico Rapaccini, Maria Di Marco, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Alberto Masotto, Franco Trevisani","doi":"10.4172/2329-6771.1000178","DOIUrl":"10.4172/2329-6771.1000178","url":null,"abstract":"<p><p>A Hepatocellular (HCC) Aggressiveness Index was recently constructed, consisting of the sum of the scores for the 4 clinical parameters of maximum tumor size, multifocality, presence of portal vein thrombus and blood alphafetoprotein levels. It was observed that there was an association with several liver function tests. We have now formed a Liver Index from the 4 liver parameters with the highest hazard ratios with respect to HCC aggressiveness, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin and platelet levels (cirrhosis surrogate). We found that the scores for the Liver Index related significantly to survival, but also to the Aggressiveness Index and to its individual HCC components as well as showing significant trends with the components. These results support the hypothesis that liver function is not only an important prognostic factor in HCC patients, but may also be involved in HCC biology and aggressiveness. Blood albumin, GGTP, albumin and platelet levels were used to create a Liver Index that related significantly to parameters of HCC aggressiveness.</p>","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"5 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35060343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-30DOI: 10.4172/2329-6771.1000E111
H. Black
Students of the life sciences (and hence oncology) have long recognized that biology obeys the same chemical and physical laws that govern all aspects of our universe. Indeed, the lines between a monolithic biology have become quite blurred between biochemistry and biophysics, the latter involving the implementation of physics methods or physics principles to the study of life and its processes. The German-American physicist, Max Delbruck, after arriving in the U.S., soon applied his physics training to biological problems. He is considered by some to be one of the founding fathers of modern molecular biology [1]. His contributions began at a time before the structure of DNA was known and Harold Varmus [2], from a plenary lecture at the American Physical Society in 1999, summarized those fundamental questions that were being asked at that time: What is the physical form in which hereditary information is stored? How is it reproduced when a cell divides? How is that information reasserted during sexual reproduction? How does that information change when mutations occur? Answers to these questions were sought employing bacteria and bacteriophage interactions-a simple model from which our knowledge of genetics was greatly advanced. In the past, physicists have made major contributions in the areas of biological energetics, enzyme and reaction kinetics, oxidation-reduction potentials, osmotic pressure and diffusion, optics, surfaces and interfaces, viscosity and liquid flow, ion transport, structure and elasticity, energetics of photoreaction centers, as well as many other areas pertinent to the study of life. Zhou [3] has summarized major research advances that have led to Nobel Prize winning contributions. Beginning with the discovery of X-rays and their diffraction by crystals that, in turn, led to the new analytical tool of X-ray crystallography. This advance made possible the determination of DNA and protein structures, the structure of photosynthetic reaction centers, ion channels, and ribosome and RNA polymerase II structures. Nuclear Magnetic Resonance Spectroscopy and the development of the Electron Microscope are examples of other contributions by physicists that have made possible the study of life, and its processes, in a detail not previously afforded and extended our horizons of investigation and depth of knowledge.
{"title":"Biophysical Contributions and Challenges in Oncology","authors":"H. Black","doi":"10.4172/2329-6771.1000E111","DOIUrl":"https://doi.org/10.4172/2329-6771.1000E111","url":null,"abstract":"Students of the life sciences (and hence oncology) have long recognized that biology obeys the same chemical and physical laws that govern all aspects of our universe. Indeed, the lines between a monolithic biology have become quite blurred between biochemistry and biophysics, the latter involving the implementation of physics methods or physics principles to the study of life and its processes. The German-American physicist, Max Delbruck, after arriving in the U.S., soon applied his physics training to biological problems. He is considered by some to be one of the founding fathers of modern molecular biology [1]. His contributions began at a time before the structure of DNA was known and Harold Varmus [2], from a plenary lecture at the American Physical Society in 1999, summarized those fundamental questions that were being asked at that time: What is the physical form in which hereditary information is stored? How is it reproduced when a cell divides? How is that information reasserted during sexual reproduction? How does that information change when mutations occur? Answers to these questions were sought employing bacteria and bacteriophage interactions-a simple model from which our knowledge of genetics was greatly advanced. In the past, physicists have made major contributions in the areas of biological energetics, enzyme and reaction kinetics, oxidation-reduction potentials, osmotic pressure and diffusion, optics, surfaces and interfaces, viscosity and liquid flow, ion transport, structure and elasticity, energetics of photoreaction centers, as well as many other areas pertinent to the study of life. Zhou [3] has summarized major research advances that have led to Nobel Prize winning contributions. Beginning with the discovery of X-rays and their diffraction by crystals that, in turn, led to the new analytical tool of X-ray crystallography. This advance made possible the determination of DNA and protein structures, the structure of photosynthetic reaction centers, ion channels, and ribosome and RNA polymerase II structures. Nuclear Magnetic Resonance Spectroscopy and the development of the Electron Microscope are examples of other contributions by physicists that have made possible the study of life, and its processes, in a detail not previously afforded and extended our horizons of investigation and depth of knowledge.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"10 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84818176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-26DOI: 10.4172/2329-6771.1000179
P. Debta
During cancer diagnosis, most patients only approach their surgeon who cut out tumors and oncologists who use potent chemotherapies and radiation to root out disease. But in this era when cancer cases are increasing, many experts are suggesting a more holistic, long-term approach that provides closer attention to the overall health of patients suffering from cancer [1]. That is why many practitioners are in favor of rapidly expanding the field of integrative oncology. Integrative Oncology fuses the best of conventional and alternative treatments [2].
{"title":"Perspectives of Integrative Oncology","authors":"P. Debta","doi":"10.4172/2329-6771.1000179","DOIUrl":"https://doi.org/10.4172/2329-6771.1000179","url":null,"abstract":"During cancer diagnosis, most patients only approach their surgeon who cut out tumors and oncologists who use potent chemotherapies and radiation to root out disease. But in this era when cancer cases are increasing, many experts are suggesting a more holistic, long-term approach that provides closer attention to the overall health of patients suffering from cancer [1]. That is why many practitioners are in favor of rapidly expanding the field of integrative oncology. Integrative Oncology fuses the best of conventional and alternative treatments [2].","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"65 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86456170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-15DOI: 10.4172/2329-6771.1000177
P. Maciej, J. Banaszewski, Tomasz Pastusiak, Agata Buczkowska, WiesÅaw Kuczko, RadosÅaw Wichniarek, F. Górski
Introduction and objective: The aim of the study was to evaluate usefulness of 3-D models utilizing generated incremental techniques from thermoplastic materials in mandibular reconstruction with utilization of free osteocutaneous fibular and scapular flaps. Methods: 12 patients were treated due to an advanced oral cavity squamous cell carcinoma (T4b). In four patients with a mandibular defect a physical 3-D model consisting of the reconstructed and unaffected sites was prepared for a reconstruction protocol. The 3-D models were designed based to high resolution CT scans. Results: Assessment of comparative functionality (stability of junction, mobility, mastication ability), and cosmetics was examined in both groups, following an 8- week healing period. Conclusion: Applying 3-D models for mandibular manufacturing using a three dimensional printing technologies allows for obtainment of better functionality of restored mandible in comparison to the traditional method. Utilization of mandibular and fibular model significantly decreases time of the operation and allows for achievement of desired shape and esthetic effect within the 1/3 of the lower face.
{"title":"Mandibular Reconstruction with Osteo-cutaneous Free Flaps in a Patient afterExtensive Surgery Supported with 3D Printed Models","authors":"P. Maciej, J. Banaszewski, Tomasz Pastusiak, Agata Buczkowska, WiesÅaw Kuczko, RadosÅaw Wichniarek, F. Górski","doi":"10.4172/2329-6771.1000177","DOIUrl":"https://doi.org/10.4172/2329-6771.1000177","url":null,"abstract":"Introduction and objective: The aim of the study was to evaluate usefulness of 3-D models utilizing generated incremental techniques from thermoplastic materials in mandibular reconstruction with utilization of free osteocutaneous fibular and scapular flaps. Methods: 12 patients were treated due to an advanced oral cavity squamous cell carcinoma (T4b). In four patients with a mandibular defect a physical 3-D model consisting of the reconstructed and unaffected sites was prepared for a reconstruction protocol. The 3-D models were designed based to high resolution CT scans. Results: Assessment of comparative functionality (stability of junction, mobility, mastication ability), and cosmetics was examined in both groups, following an 8- week healing period. Conclusion: Applying 3-D models for mandibular manufacturing using a three dimensional printing technologies allows for obtainment of better functionality of restored mandible in comparison to the traditional method. Utilization of mandibular and fibular model significantly decreases time of the operation and allows for achievement of desired shape and esthetic effect within the 1/3 of the lower face.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"55 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85306542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-10DOI: 10.4172/2329-6771.1000176
Banu Eugeniu, Zaharie Andreea, A. Serban, Buiga Rares, R. Liliana, Banu Adela Codrina
Objective: Malignant melanoma with brain metastases is associated with a higher risk of death. No specific treatments were demonstrated to be useful in a such situation. Drugs as temozolomide orally or new targeted treatments showed significant objective response rates, even complete regression. Such responses could be obtained using new strategies based on dynamic changes over time of some molecular markers. Elements of ethics should be taken into account in order to adapt treatment and avoid resistance. Methods: The case of a 59-year old male with a primary cutaneous melanoma of the trunk, treated at Cancer Institute “Ion Chiricuta” from August 2001 is presented. After multiple loco-regional relapses, the patient developed brain metastases and started temozolomide 150 mg once daily, five days, every 4 weeks, 6 cycles with concurrent whole brain external radiotherapy. Comparative immunostaining including proliferation and pro-apoptotic molecular markers between the initial diagnosis (2001), before (2005) and after (2008) temozolomide treatment was performed. Result: Nine months after the start of temozolomide treatment, complete response was confirmed by magnetic resonance imaging. Overall cancer specific survival was 41 months. Ki-67, cyclin E, HMB-45 expression and Bax/ Bcl-2 ratio increased during almost 10 years of treatment and follow-up. Bcl-2 staining was absent at the last analysis. Only p53 and Bax expression doesn't changed during treatment. Conclusion: It seems that metastatic melanoma cells lost some of pro-apoptotic markers and overexpressed markers of proliferation. Predictive markers of response and resistance were actively identified; their combination and dynamic over time could help the oncologist to select those metastatic patients with highest chances of response. Dynamic changes of these molecular markers would guide treatment and the overall core strategy. Serial biopsies and tissue analyses become a challenging ethical issue. Empiric treatments based on a unique tumor signature should be modified using an adaptive approach.
{"title":"Dynamic Changes of Molecular Markers during Natural History in Metastatic Melanoma: Ethical Issues and Lessons to Learn","authors":"Banu Eugeniu, Zaharie Andreea, A. Serban, Buiga Rares, R. Liliana, Banu Adela Codrina","doi":"10.4172/2329-6771.1000176","DOIUrl":"https://doi.org/10.4172/2329-6771.1000176","url":null,"abstract":"Objective: Malignant melanoma with brain metastases is associated with a higher risk of death. No specific treatments were demonstrated to be useful in a such situation. Drugs as temozolomide orally or new targeted treatments showed significant objective response rates, even complete regression. Such responses could be obtained using new strategies based on dynamic changes over time of some molecular markers. Elements of ethics should be taken into account in order to adapt treatment and avoid resistance. Methods: The case of a 59-year old male with a primary cutaneous melanoma of the trunk, treated at Cancer Institute “Ion Chiricuta” from August 2001 is presented. After multiple loco-regional relapses, the patient developed brain metastases and started temozolomide 150 mg once daily, five days, every 4 weeks, 6 cycles with concurrent whole brain external radiotherapy. Comparative immunostaining including proliferation and pro-apoptotic molecular markers between the initial diagnosis (2001), before (2005) and after (2008) temozolomide treatment was performed. Result: Nine months after the start of temozolomide treatment, complete response was confirmed by magnetic resonance imaging. Overall cancer specific survival was 41 months. Ki-67, cyclin E, HMB-45 expression and Bax/ Bcl-2 ratio increased during almost 10 years of treatment and follow-up. Bcl-2 staining was absent at the last analysis. Only p53 and Bax expression doesn't changed during treatment. Conclusion: It seems that metastatic melanoma cells lost some of pro-apoptotic markers and overexpressed markers of proliferation. Predictive markers of response and resistance were actively identified; their combination and dynamic over time could help the oncologist to select those metastatic patients with highest chances of response. Dynamic changes of these molecular markers would guide treatment and the overall core strategy. Serial biopsies and tissue analyses become a challenging ethical issue. Empiric treatments based on a unique tumor signature should be modified using an adaptive approach.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"63 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87579814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-22DOI: 10.4172/2329-6771.1000174
Yu-Chieh Chen, H. Lai, Wen-Ching Wang, Y. Kuo
Objective: The accurate estimation of outcome in postoperative breast cancer patients is an essential component of the individualized treatment, decision-making, and patient counseling processes. The disease outcome and prognosis of breast cancer patients may vary according to geographic and ethnic factors. To clarify this topic, we created a new prognostic and predictive model for breast cancer patients, based on clinical and pathological variables. Study design and setting: Clinical and pathological data were collected from 1587 patients with breast cancer who underwent surgical intervention. A survival prediction model was used to allow the analysis of the optimal combination of variables. The area under the receiver operating characteristic (ROC) curve, as applied to an independent validation data set, was used as the measure of accuracy. Results were assessed by comparing the area under the ROC curve with the SEER database. Results: Our predictive model of survival predicted disease outcome for individual patients with breast cancer. The comparison between our predictive model and SEER databases showed that our model underestimated outcome in the SEER cohort and that the SEER model overestimated outcome in our breast cancer patients. Conclusion: Our model may present an alternative as personalized prognostic tool for breast cancer patients. Decision regarding the survival prediction should take every consideration about regional and racial factors into account.
{"title":"Validation of Breast Cancer Survival Prediction Model with SEER Database","authors":"Yu-Chieh Chen, H. Lai, Wen-Ching Wang, Y. Kuo","doi":"10.4172/2329-6771.1000174","DOIUrl":"https://doi.org/10.4172/2329-6771.1000174","url":null,"abstract":"Objective: The accurate estimation of outcome in postoperative breast cancer patients is an essential component of the individualized treatment, decision-making, and patient counseling processes. The disease outcome and prognosis of breast cancer patients may vary according to geographic and ethnic factors. To clarify this topic, we created a new prognostic and predictive model for breast cancer patients, based on clinical and pathological variables. Study design and setting: Clinical and pathological data were collected from 1587 patients with breast cancer who underwent surgical intervention. A survival prediction model was used to allow the analysis of the optimal combination of variables. The area under the receiver operating characteristic (ROC) curve, as applied to an independent validation data set, was used as the measure of accuracy. Results were assessed by comparing the area under the ROC curve with the SEER database. Results: Our predictive model of survival predicted disease outcome for individual patients with breast cancer. The comparison between our predictive model and SEER databases showed that our model underestimated outcome in the SEER cohort and that the SEER model overestimated outcome in our breast cancer patients. Conclusion: Our model may present an alternative as personalized prognostic tool for breast cancer patients. Decision regarding the survival prediction should take every consideration about regional and racial factors into account.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"69 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79933892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-14DOI: 10.4172/2329-6771.1000E110
A. Heidari
A Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) study has been applied in a series of hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles as Non–Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and also anti–cancer Nano drugs. The molecular simulation and modeling has been investigated in three dimensions (3D) autocorrelation descriptors, obtained from different weighting schemes. Analysis of the linear and non–linear Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) simulations and models revealed a correlation coefficient and root mean square errors. The predictive ability of the simulations and models indicates that these simulations and models can be used for virtual library screening of databases for novel potent anti–cancer Nano drugs such as hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles. It should be noted that hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles as novel potent anti–cancer Nano drugs were characterized by 1HNMR, 13CNMR, 31PNMR, Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR), FT–Raman, HR Mass and UV–Vis spectroscopies and also by Scanning Electron Microscope (SEM), Transmission Electron Microscope (TEM), Differential Thermal Analysis–Thermal Gravim Analysis (DTA–TGA), Energy–Dispersive X–Ray Spectroscopy (EDX) and X–Ray Diffraction (XRD) analysis and crystallography. Ab initio and Density Functional Theory (DFT) calculations have been carried out for the hydrous Ruthenium (IV) Oxide (RuO2) anti–cancer Nano drugs by performing HF, PM3, MM2, MM3, AM1, MP2, MP3, MP4, CCSD, CCSD(T), LDA, BVWN, BLYP and B3LYP levels of theory using the standard 31G, 6–31G*, 6–31+G*, 6–31G(3df, 3pd), 6–311G, 6–311G* and 6–311+G* basis sets of the Gaussian 09.
一系列水合氧化钌(RuO2)纳米颗粒作为非核苷类逆转录酶抑制剂(NNRTIs)和抗癌纳米药物，应用定量结构-抗癌活性关系(QSACAR)研究。研究了不同加权方案下的三维自相关描述子的分子模拟和建模。线性和非线性定量结构-抗癌活性关系(QSACAR)模拟和模型分析显示相关系数和均方根误差。模拟和模型的预测能力表明，这些模拟和模型可用于新型强效抗癌纳米药物如水合氧化钌(RuO2)纳米颗粒的虚拟库筛选数据库。通过1HNMR, 13CNMR, 31PNMR，衰减全反射傅里叶变换红外(ATR-FTIR)， ft -拉曼，HR质量和紫外-可见光谱以及扫描电子显微镜(SEM)，透射电子显微镜(TEM)，差热分析-热重分析(DTA-TGA)，能量色散x射线光谱(EDX)和x射线衍射(XRD)分析和晶体学。利用高斯09的标准31G、6-31G *、6-31 +G*、6-31G (3df、3pd)、6-311G、6-311G *和6-311 +G*基集，对水合氧化钌(RuO2)抗癌纳米药物进行HF、PM3、MM2、MM3、AM1、MP2、MP3、MP4、CCSD、CCSD(T)、LDA、BVWN、BLYP和B3LYP理论水平的从头算和密度泛函理论(DFT)计算。
{"title":"Linear and Non Linear Quantitative Structure Anti Cancer Activity Relationship (QSACAR) Study of Hydrous Ruthenium (IV) Oxide (RuO2) Nanoparticles as Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Anti Cancer Nano Drugs","authors":"A. Heidari","doi":"10.4172/2329-6771.1000E110","DOIUrl":"https://doi.org/10.4172/2329-6771.1000E110","url":null,"abstract":"A Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) study has been applied in a series of hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles as Non–Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and also anti–cancer Nano drugs. The molecular simulation and modeling has been investigated in three dimensions (3D) autocorrelation descriptors, obtained from different weighting schemes. Analysis of the linear and non–linear Quantitative Structure–Anti–Cancer–Activity Relationship (QSACAR) simulations and models revealed a correlation coefficient and root mean square errors. The predictive ability of the simulations and models indicates that these simulations and models can be used for virtual library screening of databases for novel potent anti–cancer Nano drugs such as hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles. It should be noted that hydrous Ruthenium (IV) Oxide (RuO2) nanoparticles as novel potent anti–cancer Nano drugs were characterized by 1HNMR, 13CNMR, 31PNMR, Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR), FT–Raman, HR Mass and UV–Vis spectroscopies and also by Scanning Electron Microscope (SEM), Transmission Electron Microscope (TEM), Differential Thermal Analysis–Thermal Gravim Analysis (DTA–TGA), Energy–Dispersive X–Ray Spectroscopy (EDX) and X–Ray Diffraction (XRD) analysis and crystallography. Ab initio and Density Functional Theory (DFT) calculations have been carried out for the hydrous Ruthenium (IV) Oxide (RuO2) anti–cancer Nano drugs by performing HF, PM3, MM2, MM3, AM1, MP2, MP3, MP4, CCSD, CCSD(T), LDA, BVWN, BLYP and B3LYP levels of theory using the standard 31G, 6–31G*, 6–31+G*, 6–31G(3df, 3pd), 6–311G, 6–311G* and 6–311+G* basis sets of the Gaussian 09.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"45 4 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85031045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-07-13DOI: 10.4172/2329-6771.1000173
M. Rucińska, A. Kieszkowska-Grudny, Wojciech Strzelczyk, Katarzyna Bielesz, S. Nawrocki
Background: Quality of life (QoL) is an important factor for the cancer patients after treatment. The study aimed to investigate QoL and sexual activity in patients who had undergone stereotactic hypofractionated radiotherapy (HRT). Methods: The analysis included 82 prostate cancer patients: 40 patients treated by HRT (33.5 Gy in 5 fractions) and 42 patients treated by standard three-dimensional conformal radiation treatment 3DCRT (70-82 Gy in 35-41 fractions); and 50 healthy men without any type of cancer. The subjects filled out the questionnaires: EORTC QLQC30 (version 3.0.) and the prostate cancer-specific EORTC QLQ-PR25. The median follow-up was 21 months for HRT patients and 28 months for 3DCRT patients. Results: The tolerance for stereotactic HRT was shown to be good. The QoL and the general health status of HRT patients were higher than of 3DCRT patients and even of healthy men. Most patients treated by HRT felt that they had lost their masculinity. However, they were still interested in having sex; one third of them were sexually active, most reported satisfaction with their sex life. Conclusions: HRT for prostate cancer patients was an attractive treatment in relation to patients' QoL assessment in the short term analysis.
{"title":"Quality of Life and Sexual Activity after Stereotactic HypofractionatedRadiotherapy of Prostate Cancer Patients","authors":"M. Rucińska, A. Kieszkowska-Grudny, Wojciech Strzelczyk, Katarzyna Bielesz, S. Nawrocki","doi":"10.4172/2329-6771.1000173","DOIUrl":"https://doi.org/10.4172/2329-6771.1000173","url":null,"abstract":"Background: Quality of life (QoL) is an important factor for the cancer patients after treatment. The study aimed to investigate QoL and sexual activity in patients who had undergone stereotactic hypofractionated radiotherapy (HRT). Methods: The analysis included 82 prostate cancer patients: 40 patients treated by HRT (33.5 Gy in 5 fractions) and 42 patients treated by standard three-dimensional conformal radiation treatment 3DCRT (70-82 Gy in 35-41 fractions); and 50 healthy men without any type of cancer. The subjects filled out the questionnaires: EORTC QLQC30 (version 3.0.) and the prostate cancer-specific EORTC QLQ-PR25. The median follow-up was 21 months for HRT patients and 28 months for 3DCRT patients. Results: The tolerance for stereotactic HRT was shown to be good. The QoL and the general health status of HRT patients were higher than of 3DCRT patients and even of healthy men. Most patients treated by HRT felt that they had lost their masculinity. However, they were still interested in having sex; one third of them were sexually active, most reported satisfaction with their sex life. Conclusions: HRT for prostate cancer patients was an attractive treatment in relation to patients' QoL assessment in the short term analysis.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"18 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2016-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85248569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-20DOI: 10.4172/2329-6771.1000172
B. Carr, V. Guerra, E. Giannini, F. Farinati, F. Ciccarese, G. Rapaccini, M. D. Marco, L. Benvegnu', M. Zoli, F. Borzio, E. Caturelli, A. Masotto, F. Trevisani
Four HCC characteristics typically inform tumor behavior: maximum tumor size, number of nodules, portal vein thrombosis and serum AFP level. The sum of these parameters was recently published as an HCC Aggressiveness Index. We aimed to validate this index retrospectively in a larger and independent HCC cohort of 2706 Italian HCC patients, and to evaluate a possible relationship between the index and liver function parameters. The scores in the HCC Aggressiveness Index were again found to significantly relate to patient survival. Furthermore, in a multiple logistic regression model of the Aggressiveness Index score categories, there were significant differences in several liver parameter terciles amongst the score categories, suggesting a relationship of liver function to tumor aggressiveness. It was concluded that a prognostically significant Tumor Aggressiveness Index was validated and was found to be related to levels of some common liver function parameters.
{"title":"An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels","authors":"B. Carr, V. Guerra, E. Giannini, F. Farinati, F. Ciccarese, G. Rapaccini, M. D. Marco, L. Benvegnu', M. Zoli, F. Borzio, E. Caturelli, A. Masotto, F. Trevisani","doi":"10.4172/2329-6771.1000172","DOIUrl":"https://doi.org/10.4172/2329-6771.1000172","url":null,"abstract":"Four HCC characteristics typically inform tumor behavior: maximum tumor size, number of nodules, portal vein thrombosis and serum AFP level. The sum of these parameters was recently published as an HCC Aggressiveness Index. We aimed to validate this index retrospectively in a larger and independent HCC cohort of 2706 Italian HCC patients, and to evaluate a possible relationship between the index and liver function parameters. The scores in the HCC Aggressiveness Index were again found to significantly relate to patient survival. Furthermore, in a multiple logistic regression model of the Aggressiveness Index score categories, there were significant differences in several liver parameter terciles amongst the score categories, suggesting a relationship of liver function to tumor aggressiveness. It was concluded that a prognostically significant Tumor Aggressiveness Index was validated and was found to be related to levels of some common liver function parameters.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"9 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82022864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-06-06DOI: 10.4172/2329-6771.1000171
H. Masuda, Y. Fukabori, K. Nakano, M. Kobayashi, H. Yamanaka
Background: The levels of expression of Heparin binding-epidermal growth factor like growth factor (HB-EGF) mRNA in tumor tissues and normal tissues of the excised kidney were compared in order to clarify the role of HBEGF inrenal cell carcinoma (RCC) derived from the proximal tubule. Method: Normal and tumor tissues were collected from surgical specimens of 16 cases pathologically diagnosed with RCC. Total RNA was extracted from these samples, and the level of expression of HB-EGF mRNA was measured by real-time quantitative PCR using a TaqMan probe after reverse transcription. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal standard. The expression levels of HB-EGF mRNA in normal and tumor tissues of the same case were compared, and statistical analysis was performed to evaluate the association between the expression level and various clinical-pathological factors in RCC. Results: Expression of HB-EGF mRNA was detected in 82% (13/16) of the normal tissues and 63% (10/16) of the tumor tissues. The expression level in the normal tissues was significantly 7-fold higher than that in the tumor tissues. No significant association was detected between the expression of HB-EGF mRNA and the clinical stage or prognosis of RCC. However, the pathological findings indicated that negative expression of ratio of HB-EGF was higher in RCC with more-advanced malignant progression. Conclusion: Our results indicated that it was unlikely that HB-EGF might play a role in determining the aggressiveness or clinical features in RCC. However, the decreased expression of HB-EGF mRNA in RCC tissues indicates that tumorigenesis of RCC may disrupt the normal regulatory system of HB-EGF.
{"title":"Expression of Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) in Human Renal Cell Carcinoma","authors":"H. Masuda, Y. Fukabori, K. Nakano, M. Kobayashi, H. Yamanaka","doi":"10.4172/2329-6771.1000171","DOIUrl":"https://doi.org/10.4172/2329-6771.1000171","url":null,"abstract":"Background: The levels of expression of Heparin binding-epidermal growth factor like growth factor (HB-EGF) mRNA in tumor tissues and normal tissues of the excised kidney were compared in order to clarify the role of HBEGF inrenal cell carcinoma (RCC) derived from the proximal tubule. Method: Normal and tumor tissues were collected from surgical specimens of 16 cases pathologically diagnosed with RCC. Total RNA was extracted from these samples, and the level of expression of HB-EGF mRNA was measured by real-time quantitative PCR using a TaqMan probe after reverse transcription. Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as an internal standard. The expression levels of HB-EGF mRNA in normal and tumor tissues of the same case were compared, and statistical analysis was performed to evaluate the association between the expression level and various clinical-pathological factors in RCC. Results: Expression of HB-EGF mRNA was detected in 82% (13/16) of the normal tissues and 63% (10/16) of the tumor tissues. The expression level in the normal tissues was significantly 7-fold higher than that in the tumor tissues. No significant association was detected between the expression of HB-EGF mRNA and the clinical stage or prognosis of RCC. However, the pathological findings indicated that negative expression of ratio of HB-EGF was higher in RCC with more-advanced malignant progression. Conclusion: Our results indicated that it was unlikely that HB-EGF might play a role in determining the aggressiveness or clinical features in RCC. However, the decreased expression of HB-EGF mRNA in RCC tissues indicates that tumorigenesis of RCC may disrupt the normal regulatory system of HB-EGF.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84214296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号